Science Explorer Back to mapMap
Discussion
Researcher · Ludwig Cancer Research · Sweden

Carl‐Henrik Heldin

Carl‐Henrik Heldin publishes mostly in Molecular Biology, Oncology and Cell Biology, on topics such as TGF-β signaling in diseases, Cell Adhesion Molecules Research and Protein Kinase Regulation and GTPase Signaling.

ORCID 0000-0002-9508-896X OpenAlex
World rank
#22,659
of 7,710,434 ranked researchers
Rank in Sweden
#123
of 71,437
Works
640
Citations
77k
Citations per work
120.5
h-index
145
i10-index 464Top 0.1% in Molecular Biology
Carl‐Henrik Heldin

What does Carl‐Henrik Heldin research?

Carl‐Henrik Heldin's work is mostly in Biochemistry, Genetics and Molecular Biology (52%), Medicine (18%).

Life Sciences: 335 works · 52.4% of their workBiochemistry, Genetics and Molecular Biology: 335 works · 52.4% of their workMolecular Biology: 275 works · 43.0% of their workCell Biology: 33 works · 5.1% of their workCancer Research: 28 works · 4.3% of their workEverything else: 186 works · 29.1% of their workHealth Sciences: 118 works · 18.5% of their workMedicine: 118 works · 18.5% of their workOncology: 63 works · 9.9% of their workHematology: 28 works · 4.3% of their workImmunology and Allergy: 28 works · 4.3% of their workTHEIR WORKCarl‐HenrikHeldin640works
Life Sciences52%Health Sciences18%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology33552.4%
  2. Everything else18629.1%
    1. Medicine11818.5%
  1. 1Molecular Biology43% of their works
  2. 2Oncology10% of their works
  3. 3Cell Biology5% of their works
  4. 4Immunology and Allergy4% of their works
  5. 5Cancer Research4% of their works
  6. 6Hematology4% of their works

Research topics

Which keywords describe Carl‐Henrik Heldin's research?

The keywords of their largest research topics: Angiogenesis, Smad-dependent pathways, Tumor Suppression, Inflammation, Cancer, Metabolism, Signaling and Cell Adhesion.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 21 words, with their numbers
  1. Angiogenesis3063 topics
  2. Smad-dependent pathways1821 topic
  3. Tumor Suppression1821 topic
  4. Inflammation1733 topics
  5. Cancer1683 topics
  6. Metabolism922 topics
  7. Signaling922 topics
  8. Cell Adhesion761 topic
  9. Integrins761 topic
  10. Protein Kinases551 topic
  11. Ras Signaling551 topic
  12. Platelets491 topic
  13. Thrombosis491 topic
  14. Hyaluronan481 topic
  15. Proteoglycans481 topic
  16. PI3K/AKT pathway471 topic
  17. mTOR471 topic
  18. FGF21451 topic
  19. Fibroblast Growth Factor451 topic
  20. VEGF451 topic
  21. endothelial progenitor cells451 topic

Where does Carl‐Henrik Heldin work?

Carl‐Henrik Heldin's main affiliation in the publication record is Ludwig Cancer Research, Sweden.

How many publications and citations does Carl‐Henrik Heldin have?

OpenAlex counts 640 works and 77,129 citations for Carl‐Henrik Heldin, an h-index of 145, ranking #22,659 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Other researchers named Carl‐Henrik Heldin

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Carl‐Henrik Heldin. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.